The potential of nanoscale combinations of self-assembling peptides and amino acids of the Src tyrosine kinase inhibitor in acute lung injury therapy

Biomaterials

Volumn 32, Issue 16, 2011, Pages 4000-4008

  Fung, Shan Yu ^a   Oyaizu, Takeshi ^a   Yang, Hong ^a   Yuan, Yongfang ^a   Han, Bing ^a   Keshavjee, Shaf ^a,b   Liu, Mingyao ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Acute inflammatory response; Biocompatibility; Drug delivery; Nanoformulation; Self assembling peptide

Indexed keywords

ACUTE INFLAMMATORY RESPONSE; ACUTE LUNG INJURY; BRONCHOALVEOLAR LAVAGE FLUID; CLINICAL APPLICATION; CULTURED CELL; CYTOKINES; INFLAMMATORY CELLS; INTRATRACHEAL; LIPOPOLYSACCHARIDES; MOUSE MODELS; NANO SCALE; NANOFORMULATION; PRE-TREATMENT; SELF-ASSEMBLING PEPTIDE; SELF-ASSEMBLING PEPTIDES; THERAPEUTIC AGENTS; THERAPEUTIC EFFICACY; TYROSINE KINASE INHIBITOR;

BIOCOMPATIBILITY; BIOLOGICAL ORGANS; DRUG DELIVERY; ENZYME INHIBITION; ENZYMES; NANOSTRUCTURED MATERIALS; ORGANIC SOLVENTS; PEPTIDES; SELF ASSEMBLY;

AMINO ACIDS;

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; AMINO ACID DERIVATIVE; DIMETHYL SULFOXIDE; LIPOPOLYSACCHARIDE; NANOMATERIAL; PEPTIDE DERIVATIVE; PROTEIN TYROSINE KINASE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG FORMULATION; ENZYME INHIBITION; HYDROPHOBICITY; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ACUTE LUNG INJURY; AMINO ACIDS; ANIMALS; BLOTTING, WESTERN; CELL LINE; HEMOLYSIS; HUMANS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; NIH 3T3 CELLS; OLIGOPEPTIDES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79953028732     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.02.005     Document Type: Article

References (34)

1. Zhang S. Fabrication of novel biomaterials through molecular self-assembly. Nat Biotechnol 2003, 21:1171-1178.
2. Zhang S., Holmes T., Lockshin C., Rich A. Spontaneous assembly of a self-complementary oligopeptide to form a stable macroscopic membrane. Proc Natl Acad Sci U S A 1993, 90:3334-3338.
3. Zhang S., Holmes T., DiPersio C.M., Hynes R.O., Su X., Rich A. Self-complementary oligopeptide matrices support mammalian cell attachment. Biomaterials 1995, 16:1385-1393.
4. Fung S.Y., Yang H., Chen P. Sequence effect of self-assembling peptides on the complexation and in vitro delivery of the hydrophobic anticancer drug ellipticine. PLoS One 2008, 3:e1956.
5. Fung S.Y., Yang H., Bhola P.T., Sadatmousavi P., Muzar E., Liu M., et al. Self-assembling peptide as a potential carrier for hydrophobic anticancer drug ellipticine: complexation, release and in vitro delivery. Adv Funct Mater 2009, 19:74-83.
6. Law M., Jafari M., Chen P. Physicochemical characterization of siRNA-peptide complexes. Biotechnol Prog 2008, 24:957-963.
7. Arakawa T., Tsumoto K., Kita Y., Chang B., Ejima D. Biotechnology applications of amino acids in protein purification and formulations. Amino Acids 2007, 33:587-605.
8. Phua J., Badia J.R., Adhikari N.K., Friedrich J.O., Fowler R.A., Singh J.M., et al. Has mortality from acute respiratory distress syndrome decreased over time?: a systematic review. Am J Respir Crit Care Med 2009, 179:220-227.
9. Okutani D., Lodyga M., Han B., Liu M. Src protein tyrosine kinase family and acute inflammatory responses. Am J Physiol Lung Cell Mol Physiol 2006, 291:L129-L141.
10. Hanke J.H., Gardner J.P., Dow R.L., Changelian P.S., Brissette W.H., Weringer E.J., et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 1996, 271:695-701.
11. Khadaroo R.G., He R., Parodo J., Powers K.A., Marshall J.C., Kapus A., et al. The role of the Src family of tyrosine kinases after oxidant-induced lung injury in vivo. Surgery 2004, 136:483-488.
12. Severgnini M., Takahashi S., Tu P., Perides G., Homer R.J., Jhung J.W., et al. Inhibition of the Src and Jak kinases protects against lipopolysaccharide-induced acute lung injury. Am J Respir Crit Care Med 2005, 171:858-867.
13. Lee H.S., Moon C., Lee H.W., Park E.M., Cho M.S., Kang J.L. Src tyrosine kinases mediate activations of NF-kappaB and integrin signal during lipopolysaccharide-induced acute lung injury. J Immunol 2007, 179:7001-7011.
14. Han B., Bai X.H., Lodyga M., Xu J., Yang B.B., Keshavjee S., et al. Conversion of mechanical force into biochemical signaling. J Biol Chem 2004, 279:54793-54801.
15. Lodyga M., De Falco V., Bai X.H., Kapus A., Melillo R.M., Santoro M., et al. XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway. Oncogene 2009, 28:937-949.
16. Han B., Haitsma J.J., Zhang Y., Bai X., Rubacha M., Keshavjee S., et al. Long pentraxin PTX3 deficiency worsens LPS-induced acute lung injury. Intensive Care Med 2010.
17. He X., Han B., Bai X., Zhang Y., Cypel M., Mura M., et al. PTX3 as a potential biomarker of acute lung injury: supporting evidence from animal experimentation. Intensive Care Med 2010, 36:356-364.
18. Mura M., Han B., Andrade C.F., Seth R., Hwang D., Waddell T.K., et al. The early responses of VEGF and its receptors during acute lung injury: implication of VEGF in alveolar epithelial cell survival. Crit Care 2006, 10:R130.
19. Rubin L.F. Toxicity of dimethyl sulfoxide, alone and in combination. Ann N Y Acad Sci 1975, 243:98-103.
20. Fung S.Y., Keyes C., Duhamel J., Chen P. Concentration effect on the aggregation of a self-assembling oligopeptide. Biophys J 2003, 85:537-548.
21. Roskoski R. Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Commun 2004, 324:1155-1164.
22. Matute-Bello G., Frevert C.W., Martin T.R. Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2008, 295:L379-L399.
23. Wang H.M., Bodenstein M., Markstaller K. Overview of the pathology of three widely used animal models of acute lung injury. Eur Surg Res 2008, 40:305-316.
24. Sauer-Heilborn A., Kadidlo D., McCullough J. Patient care during infusion of hematopoietic progenitor cells. Transfusion 2004, 44:907-916.
25. Santos N.C., Figueira-Coelho J., Martins-Silva J., Saldanha C. Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Biochem Pharmacol 2003, 65:1035-1041.
26. Hameroff S.R., Otto C.W., Kanel J., Weinstein P.R., Blitt C.D. Acute cardiovascular effects of dimethyl sulfoxide. Ann N Y Acad Sci 1983, 411:94-99.
27. Rubin L.F. Toxicologic update of dimethyl sulfoxide. Ann N Y Acad Sci 1983, 411:6-10.
28. Yu Z.W., Quinn P.J. The modulation of membrane structure and stability by dimethyl sulphoxide (review). Mol Membr Biol 1998, 15:59-68.
29. Davis M.E., Michael Motion J.P., Narmoneva D.A., Takahashi T., Hakuno D., Kamm R.D., et al. Injectable self-assembling peptide nanofibers create intramyocardial microenvironments for endothelial cells. Circulation 2005, 111:442-450.
30. Ellis-Behnke R.G., Liang Y.-X., You S.-W., Tay D.K.C., Zhang S., So K.-F., et al. Nano neuro knitting: peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision. Proc Natl Acad Sci U S A 2006, 103:5054-5059.
31. Holmes T.C., de Lacalle S., Su X., Liu G., Rich A., Zhang S. Extensive neurite outgrowth and active synapse formation on self-assembling peptide scaffolds. Proc Natl Acad Sci U S A 2000, 97:6728-6733.
32. Chen B., Bautista R., Yu K., Zapata G.A., Mulkerrin M.G., Chamow S.M. Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms. Pharm Res 2003, 20:1952-1960.
33. Gertz M.A. New targets and treatments in multiple myeloma: Src family kinases as central regulators of disease progression. Leuk Lymphoma 2008, 49:2240-2245.
34. Hayakawa F., Naoe T. SFK-STAT pathway: an alternative and important way to malignancies. Ann N Y Acad Sci 2006, 1086:213-222.